- Report
- November 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- April 2023
- 394 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Clinical Trials
- April 2024
- 150 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- March 2024
- 225 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- April 2023
- 200 Pages
United States
From €3413EUR$3,750USD£2,926GBP
- Report
- May 2023
- 147 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- January 2022
- 121 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- October 2021
- 131 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- September 2024
- 231 Pages
China
From €3640EUR$4,000USD£3,121GBP
- Report
- January 2024
- 345 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- January 2024
- 321 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- December 2023
- 394 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- November 2023
- 224 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- September 2024
- 74 Pages
China
From €1638EUR$1,800USD£1,404GBP
- Report
- September 2024
- 103 Pages
China
From €1638EUR$1,800USD£1,404GBP

Cisplatin is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It works by damaging the DNA of cancer cells, preventing them from growing and dividing. Cisplatin is often used in combination with other drugs to increase its effectiveness. It is administered intravenously and can cause side effects such as nausea, vomiting, and hair loss.
The market for cisplatin in the treatment of lung cancer is highly competitive, with many companies offering their own versions of the drug. Companies such as Bristol-Myers Squibb, Pfizer, and Merck & Co. are all major players in the market. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of the drug.
In the market for cisplatin, companies such as Bristol-Myers Squibb, Pfizer, Merck & Co., Teva Pharmaceuticals, and Mylan are all major players. Show Less Read more